GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » FCF Yield %

BRNS (Barinthus Biotherapeutics) FCF Yield % : -108.34 (As of Apr. 10, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Barinthus Biotherapeutics's Trailing 12-Month Free Cash Flow is $-29.83 Mil, and Market Cap is $27.54 Mil. Therefore, Barinthus Biotherapeutics's FCF Yield % for today is -108.34%.

The historical rank and industry rank for Barinthus Biotherapeutics's FCF Yield % or its related term are showing as below:

BRNS' s FCF Yield % Range Over the Past 10 Years
Min: -176.05   Med: -21.24   Max: -2.69
Current: -108.34


During the past 6 years, the highest FCF Yield % of Barinthus Biotherapeutics was -2.69%. The lowest was -176.05%. And the median was -21.24%.

BRNS's FCF Yield % is ranked worse than
82.78% of 1498 companies
in the Biotechnology industry
Industry Median: -16.365 vs BRNS: -108.34

Barinthus Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.


Barinthus Biotherapeutics FCF Yield % Historical Data

The historical data trend for Barinthus Biotherapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics FCF Yield % Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
Get a 7-Day Free Trial - -8.16 -23.23 -39.51 -61.38

Barinthus Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.56 -52.34 -88.94 -155.66 105.41

Competitive Comparison of Barinthus Biotherapeutics's FCF Yield %

For the Biotechnology subindustry, Barinthus Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's FCF Yield % falls into.


;
;

Barinthus Biotherapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Barinthus Biotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-29.832 / 48.60388
=-61.38%

Barinthus Biotherapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=12.808 * 4 / 48.60388
=105.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Barinthus Biotherapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Barinthus Biotherapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Barinthus Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Executives
Joseph Scheeren director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright director, officer: Chief Executive Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier officer: Chief Scientific Officer C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown officer: Chief Financial Officer VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths officer: Chief Business Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis officer: Chief Operating Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall officer: Chief Medical Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans officer: Chief Scientific Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov officer: Chief Financial Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE